-
1PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivitypor Doumet Georges Helou, Pedram Shafiei-Jahani, Richard Lo, Emily Howard, Benjamin P. Hurrell, Lauriane Galle-Treger, Jacob D. Painter, Gavin Lewis, Pejman Soroosh, Arlene H. Sharpe, Omid Akbari“...PD-1 is a checkpoint inhibitory immune receptor that restrains proliferation and effector functions...”
Publicado 2020
Enlace del recurso
article -
2por Antje Kroner, Nicholas Schwab, Chi Wang Ip, Christoph Leder, Klaus-Armin Nave, Mathias Mäurer, Heinz Wiendl, Rudolf Martini“... inflammation (PLPtg-mutants). The focus was on the role of the co-inhibitory molecule PD-1, a CD28-related...”
Publicado 2009
Enlace del recurso
article -
3por Shuguang Tan, Hao Zhang, Yan Chai, Hao Song, Zhou Tong, Qihui Wang, Jianxun Qi, Gary Wong, Xiaodong Zhu, William J. Liu, Shan Gao, Zhongfu Wang, Yi Shi, Fuquan Yang, George F. Gao, Jinghua Yan“...Programmed cell death 1 (PD-1) is a key target for cancer immunotherapy. Here the authors present...”
Publicado 2017
Enlace del recurso
article -
4por Miguel Angel Galván Morales, Josaphat Miguel Montero-Vargas, Juan Carlos Vizuet-de-Rueda, Luis M TeranMaterias: “...PD-1...”
Publicado 2021
Enlace del recurso
article -
5
-
6
-
7por Rajasekharan Somasundaram, Thomas Connelly, Robin Choi, Hyeree Choi, Anastasia Samarkina, Ling Li, Elizabeth Gregorio, Yeqing Chen, Rohit Thakur, Mohamed Abdel-Mohsen, Marilda Beqiri, Meaghan Kiernan, Michela Perego, Fang Wang, Min Xiao, Patricia Brafford, Xue Yang, Xiaowei Xu, Anthony Secreto, Gwenn Danet-Desnoyers, Daniel Traum, Klaus H. Kaestner, Alexander C. Huang, Denitsa Hristova, Joshua Wang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Fang Ping-Chen, Xiangyang Zhou, Alexis Gutierrez, Vito W. Rebecca, Prashanthi Vonteddu, Farokh Dotiwala, Shashi Bala, Sonali Majumdar, Harsh Dweep, Jayamanna Wickramasinghe, Andrew V. Kossenkov, Jorge Reyes-Arbujas, Kenisha Santiago, Tran Nguyen, Johannes Griss, Frederick Keeney, James Hayden, Brian J. Gavin, David Weiner, Luis J. Montaner, Qin Liu, Lukas Peiffer, Jürgen Becker, Elizabeth M. Burton, Michael A. Davies, Michael T. Tetzlaff, Kar Muthumani, Jennifer A. Wargo, Dmitry Gabrilovich, Meenhard HerlynEnlace del recurso
Publicado 2021
article -
8por Zhaohan Wei, Xiaoqiong Zhang, Tuying Yong, Nana Bie, Guiting Zhan, Xin Li, Qingle Liang, Jianye Li, Jingjing Yu, Gang Huang, Yuchen Yan, Zelong Zhang, Bixiang Zhang, Lu Gan, Bo Huang, Xiangliang Yang“...Durable response rate to anti-PD-1/PD-L1 therapy remains relatively low in patients with cancer...”
Publicado 2021
Enlace del recurso
article -
9por Chang-Jin Jung, Hee-Joo Yang, Seung-Hyun Bang, Woo-Jin Lee, Chong-Hyun Won, Mi-Woo Lee, Youngsup Song, Sung-Eun ChangMaterias: “...epidermal PD-1...”
Publicado 2021
Enlace del recurso
article -
10por Chun-Yu Chen, Pin-Yi Wang, Brian Hutzen, Les Sprague, Hayley M. Swain, Julia K. Love, Joseph R. Stanek, Louis Boon, Joe Conner, Timothy P. Cripe“... inhibitory ligands to inhibit antitumor T cell function. Blocking programmed cell death protein (PD)-1...”
Publicado 2017
Enlace del recurso
article -
11por Florie Bertrand, Anne Montfort, Elie Marcheteau, Caroline Imbert, Julia Gilhodes, Thomas Filleron, Philippe Rochaix, Nathalie Andrieu-Abadie, Thierry Levade, Nicolas Meyer, Céline Colacios, Bruno Ségui“...Most melanoma patients do not respond to anti-PD1 therapy. Here, the authors show that TNFα...”
Publicado 2017
Enlace del recurso
article -
12por González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R“... to pharmacological design of antibodies against immune checkpoint inhibitors. Anti-PD-1/PD-L1 antibodies...”
Publicado 2015
Enlace del recurso
article -
13
-
14
-
15
-
16por Anniina Färkkilä, Doga C. Gulhan, Julia Casado, Connor A. Jacobson, Huy Nguyen, Bose Kochupurakkal, Zoltan Maliga, Clarence Yapp, Yu-An Chen, Denis Schapiro, Yinghui Zhou, Julie R. Graham, Bruce J. Dezube, Pamela Munster, Sandro Santagata, Elizabeth Garcia, Scott Rodig, Ana Lako, Dipanjan Chowdhury, Geoffrey I. Shapiro, Ursula A. Matulonis, Peter J. Park, Sampsa Hautaniemi, Peter K. Sorger, Elizabeth M. Swisher, Alan D. D’Andrea, Panagiotis A. Konstantinopoulos“... in combination with the PD-1 inhibitor pembrolizumab in platinum-resistant ovarian cancer patients. Here...”
Publicado 2020
Enlace del recurso
article -
17por Kaitao Li, Zhou Yuan, Jintian Lyu, Eunseon Ahn, Simon J. Davis, Rafi Ahmed, Cheng Zhu“...The mechanistic detail of how PD-1 inhibits T cell activation is lacking. Here, the authors show PD...”
Publicado 2021
Enlace del recurso
article -
18por Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana M. Kulkarni, Mari Kuraguchi, Sangeetha Palakurthi, Peter E. Fecci, Bruce E. Johnson, Pasi A. Janne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok-Kin Wong, Peter S. HammermanEnlace del recurso
Publicado 2016
article -
19Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancerpor Hongji Zhang, Yu Wang, Amblessed Onuma, Jiayi He, Han Wang, Yujia Xia, Rhea Lal, Xiang Cheng, Gyulnara Kasumova, Zhiwei Hu, Meihong Deng, Joal D. Beane, Alex C. Kim, Hai Huang, Allan TsungMaterias: “...programmed cell death protein 1 (PD-1)...”
Publicado 2021
Enlace del recurso
article -
20por Zhitao Li, Guoqiang Sun, Guangshun Sun, Ye Cheng, Liangliang Wu, Qian Wang, Chengyu Lv, Yichan Zhou, Yongxiang Xia, Weiwei TangMaterias: “...PD-1/PD-L1 inhibitors...”
Publicado 2021
Enlace del recurso
article